- Title
- LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
- Creators
- N. Colombo - European Institute of OncologyC. Dubot - Institute CurieD. Lorusso - Agostino Gemelli University PolyclinicV. Cáceres - Instituto de Oncología de RosarioK. Hasegawa - Saitama Medical UniversityR. Shapira-Frommer - Sheba Medical CenterK.S. Tewari - University of California, IrvineP. Salman - Medical Oncology, Oncovida Cancer Center, Providencia, Santiago, ChileE. Hoyos - OncoMedE. Yañez - Medical Oncology, Universidad de la Frontera, Temuco, ChileM. Gumus - Istanbul Medeniyet UniversityM. Olivera Hurtado de Mendoza - Instituto Nacional de Enfermedades NeoplásicasV. Samouëlian - Centre Hospitalier de l’Université de MontréalV. Castonguay - Centre Hospitalier Universitaire de QuébecA. Arkhipov - Oncology and chemical therapy, Medical Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russian FederationS. Toker - MSDK. Li - MSDS.M. Keefe - MSDB.J. Monk - Creighton University
- Publication Details
- Annals of oncology, Vol.32, pp.S1307-S1308
- Publisher
- Elsevier Ltd
- Identifiers
- 991005969013102656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Annals of oncology, Vol.32, pp.S1307-S1308
09/2021
Metrics
3 Record Views